Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04985708 · ClinicalTrials.gov registry record
Carolinas Cardiogenic Shock Initiative
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 120
- Enrollment target
NCT04985708: Completed study, sponsored by Wake Forest University Health Sciences.
NCT04985708 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04985708 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
To determine if deferred or delayed implantation of Impella device based on shock severity index is non-inferior with respect to 1 month and 1 year mortality compared to standard clinical protocols that do not differentiate based on shock severity in adult patients following an initial diagnosis of acute myocardial infarction complicated by cardiogenic shock (AMICS).
Primary Outcome
Survival at 30 days post procedure
Interventions
- OTHER data collection of clinically available procedures
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2022-05-31 |
What the finished NCT04985708 record still lists
NCT04985708 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which data collection of clinically available procedures is the first listed.
NCT04985708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04985708 about?
NCT04985708 is a clinical study titled "Carolinas Cardiogenic Shock Initiative". To determine if deferred or delayed implantation of Impella device based on shock severity index is non-inferior with respect to 1 month and 1 year mortality compared to standard clinical protocols that do not differentiate based on shock severity in adult patients following an initial diagnosis of ...
What is the current status of trial NCT04985708?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2019-05-01. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04985708?
The interventions under investigation include: data collection of clinically available procedures (OTHER).
Who is sponsoring clinical trial NCT04985708?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI